Status: Recruiting
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Updated: Oct 21, 2024Locations: 1
Eligibility criteria
Age:18-75 years old [+4]
Known uncontrolled or symptomatic central nervous system metastatic disease. [+4]